Talee Bio is a gene therapy company with a focus in leading on the treatment of cystic fibrosis. The company’s gene therapy technologies are designed to have the ability to carry a large payload via an adeno-associated viral and a lentiviral gene therapy platform. Each has been developed to be highly tropic to human airway epithelia and, therefore, to overcome the biggest limitation to using gene therapy to treat or cure cystic fibrosis. Talee Bio’s founders and collaborators at The University of Iowa and Children’s Hospital of Philadelphia have over 100 years of experience in cystic fibrosis biology, pathophysiology and gene therapy.

Venture Information
Stage: 
Product Development
Industry: 
Diagnostics
Technology or Science Area: 
Cystic fibrosis gene therapy.
Market: 
Cystic fibrosis treatment and gene therapy market.
Funding Round: 
Angel
Company Information
Founders: 
Michael Welsh
John F Engelhardt
Joseph Zabner
Paul McCray
Beverly L Davidson